

Amendments to the Specification:

Please insert the following after page 55, on a new page 56:

Abstract Of The Disclosure

The use of P- and A-type IPGs or their antagonists in the treatment of diabetes is disclosed. In particular, the present invention provides treatment of IDDM or lean type II diabetes (NIDDM) with a mixture of P- and A-type mediators, and treatment of obese type II diabetes (NIDDM) with a P-type mediator and/or an A-type antagonist.

Please add the following new paragraph at line 4 on page 1 of the specification:

Cross-Reference To Related Applications

This application is a continuation of US App. No. 09/254,800, filed June 11, 1999; which is a 371 of App. No. PCT/GB97/02440, filed September 11, 1997, which claims the benefit of GB App. No. 9618934.5, filed September 11, 1996 the disclosures of which are hereby incorporated by reference in their entirety.